Viral Vector and Plasmid DNA Manufacturing Market Size is Estimated to be around USD 3 billion by 2035

Vectors are the biological tools that are used to transport genetic material to the target cell. Over the past decade, these viral and non viral vectors have emerged as the key pre-requisites for developing cell and gene therapies. It is worth mentioning that, till 2023, around 35 cell and gene therapy products have been approved by the FDA.

Notably, in the US alone, more than 200 viral vector-based gene therapy drug candidates are currently undergoing clinical evaluation for various indications. The increased number of cell and gene therapy approvals, and ongoing clinical trials related to viral vector-based gene therapy has resulted in an evident rise in the demand for large scale viral vector manufacturing.

However, viral vectors as delivery vehicles are fraught with certain challenges, including high risk for cytotoxicity, insertional mutagenesis and complexity in characterization; as a result, the drug developers are actively evaluating the potential of non-viral vectors.

According to Roots Analysis, theviral vector and plasmid DNA manufacturing market is estimated to be worth USD 926.5 million in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 11.11% during the forecast period 2024-2035.

Market Drivers

Several factors are contributing to the growth of the viral vector manufacturing market, including the growing demand for gene therapies, increased investment in vaccine development, and prevalence of genetic disorders, infectious diseases, and oncological disorders.

Moreover, the use of cost-effective and scalable technology platforms in the manufacturing of vectors is expected to improve the efficiency of the production process, thereby driving the growth of the non viral vector and viral vector manufacturing market.

Market Restraints

While non viral vector and viral vector manufacturing market is experiencing steady growth, it is also fraught with several challenges. One of the primary restraints include the lack of regulatory predictability and harmonization among different regulatory authorities, owing to which manufacturing and distribution of the non viral vectors and viral vectors has become a complex and tedious process.

Growth Factors

Despite the challenges, several growth factors are contributing to drive the non viral vector and viral vector manufacturing market. One of the primary factors include ongoing technological advancements and the adoption of digital tools in viral vector manufacturing that ensure operational excellence and improve occupational safety of the employees.

Further, considering the increasing pace of innovation and research activity, the non viral vector and viral vector manufacturing market is anticipated to witness a steady growth in the foreseen future.

Viral Vector and Plasmid DNA Manufacturing Market Segments

Based on the scale of operation, the market is segmented into preclinical, clinical, and commercial

The clinical scale of operation led the market, capturing the largest revenue share in 2024.

The commercial scale of operation is anticipated to show the highest growth potential by growing at a CAGR of nearly 15%, during the forecast period.

Based on the type of vector, the market is segmented into adeno-associated viral vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, non viral vectors, and other vectors

The lentiviral vectors segment led the viral vector and plasmid DNA manufacturing market, capturing the largest revenue share of more than 30% in 2024.

This can be attributed to the fact that several lentiviral vector-based gene therapies and cell therapies are currently in the late stages of clinical development. Further, this trend is likely to remain same in the coming years due to certain distinguishing characteristics of lentiviral vectors, including capability of transducing both dividing and nondividing cells, enable long?term gene expression, and reduced risk of genotoxicity and insertional mutagenesis.

Based on the application area, the market is segmented into cell therapies, gene therapies, and vaccines

The cell therapies segment led the market for viral vector and plasmid DNA manufacturing, capturing the largest revenue share of more than 60% in 2024.

The vaccines segment is anticipated to show the highest growth potential by growing at a CAGR of over 11.5% during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, rare diseases, immunological disorders, neurological disorders, sensory disorders, metabolic disorders, blood disorders, musculoskeletal disorders, infectious diseases, ophthalmic disorders, autoimmune disorders, and other disorders

The oncological disorders segment led the market for viral vector and plasmid DNA manufacturing, capturing the largest revenue share of over 45% in 2024.

This can be attributed to the growing incidence of oncological disorders, globally, which necessitates the development and production of effective treatments.

Based on the type of manufacturer, the market is segmented into in-house manufacturers and contract manufacturing organizations

The contract manufacturing organizations led the market for viral vector and plasmid DNA manufacturing, capturing the largest revenue share of nearly 60% in 2024.

The contract manufacturing services are likely to dominate the market, till 2035; this can be attributed to various factors including availability of skilled workforce and advanced infrastructure dedicated to vector production, purification, and quality control.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America and Rest of the World

North America dominated the viral vector and plasmid DNA manufacturing market and accounted for the largest revenue share of over 40% in 2024.

This trend is likely to remain the same in the coming years, as the number of approved advanced therapy medicinal products is likely to increase several folds in this region.

Key Companies Profiled

The plasmid DNA and viral vector manufacturing market report also includes profiles of key players (listed below) that are engaged in manufacturing vectors and gene therapies: Advanced BioScience Laboratories, AGC Biologics, Aldevron, Altruist Biotechnology, BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech), BioReliance (a subsidiary of Merck KGaA), Biovian, Celonic, Catalent Biologics, Cobra Biologics, Celonic, Centre for Process Innovation, CEVEC Pharmaceuticals, Charles River Laboratories, CoJourney, Esco Aster, Jiangsu Puxin Biopharmaceutical, Lonza, Matica Biotechnology, Nikon CeLL innovation, NorthX Biologics, Novartis, Oxford BioMedica, Resilience, Sanofi, Thermo Fisher Scientific, VectorBuilder, Wuxi AppTech

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary

+1 (857) 387 7999
+44 (748) 188 1310

Email: sales@rootsanalysis.com